AFFiRiS AG

Alzheimer's
Parkinson's
- AFFiRiS Clinical trials
Atherosclerosis
Hypertension

Welcome

AFFiRiS is an innovative, Vienna-based biotechnology company. Using its proprietary AFFITOME® - technology, it is able to develop customised peptide-based vaccines targeting Alzheimer’s disease, Parkinson's disease, atherosclerosis, hypertension and other diseases with unmet medical needs.

AFFiRiS was founded by Dr. Walter Schmidt (CEO) and Dr. Frank Mattner (CSO) in late 2003. Based on its business model and its globally unique expertise, AFFiRiS aims to initiate the clinical testing of a new vaccine against thus-far incurable diseases every 2 to 3 years.

News

Parkinson’s Vaccine – Worldwide First Clinical Study in Vienna

Vienna (Austria), 5. June 2012. The worldwide first clinical trial for the development of a Parkinson’s vaccine has now been started by AFFiRiS AG.

more